Latest news with #PaulHudson
Yahoo
23-07-2025
- Business
- Yahoo
$515M Bet on Musk, AI, and Space: Glade Brook Goes All-In While Others Retreat
Glade Brook Capital Partners just pulled in $515 million for its fourth fund and it's placing its bets on the edge of what's next: AI, space, defense, and fintech. The firm, which already holds stakes in SpaceX, Stripe, and Elon Musk's Neuralink, plans to double down on late-stage tech startups navigating some of the most volatile capital markets in recent memory. Founder Paul Hudson didn't sugarcoat the conditions, calling it the most challenging fundraising environment he's seen in his career even as the fund ended up oversubscribed. Despite the headwinds, Glade Brook is leaning into momentum. It's already backing Musk's xAI and Artisan AI, signaling a clear tilt toward artificial intelligence. That comes on top of a portfolio that includes ramping fintech player Ramp and previously backed giants like Uber (NYSE:UBER) and Airbnb (NASDAQ:ABNB). And in a move that tracks closely with broader market appetite, the firm is betting that innovation in complex, capital-intensive sectors like AI and defense could offer asymmetric upside if timed right. Tesla (NASDAQ:TSLA) remains part of the broader Musk-aligned orbit Glade Brook is exposed to, adding even more edge to its late-stage tech focus. Their 2021 fund a $430 million vehicle reportedly ranks in the top 5% of its vintage, according to private Cambridge Associates data. While past performance doesn't guarantee future returns, it does suggest Glade Brook knows how to play late-stage cycles. In a market where many VCs are stuck in wait-and-see mode, Glade Brook appears to be playing offense betting that when the next wave breaks, it'll be the firms already in position that ride it the farthest. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-07-2025
- Business
- Yahoo
$515M Bet on Musk, AI, and Space: Glade Brook Goes All-In While Others Retreat
Glade Brook Capital Partners just pulled in $515 million for its fourth fund and it's placing its bets on the edge of what's next: AI, space, defense, and fintech. The firm, which already holds stakes in SpaceX, Stripe, and Elon Musk's Neuralink, plans to double down on late-stage tech startups navigating some of the most volatile capital markets in recent memory. Founder Paul Hudson didn't sugarcoat the conditions, calling it the most challenging fundraising environment he's seen in his career even as the fund ended up oversubscribed. Despite the headwinds, Glade Brook is leaning into momentum. It's already backing Musk's xAI and Artisan AI, signaling a clear tilt toward artificial intelligence. That comes on top of a portfolio that includes ramping fintech player Ramp and previously backed giants like Uber (NYSE:UBER) and Airbnb (NASDAQ:ABNB). And in a move that tracks closely with broader market appetite, the firm is betting that innovation in complex, capital-intensive sectors like AI and defense could offer asymmetric upside if timed right. Tesla (NASDAQ:TSLA) remains part of the broader Musk-aligned orbit Glade Brook is exposed to, adding even more edge to its late-stage tech focus. Their 2021 fund a $430 million vehicle reportedly ranks in the top 5% of its vintage, according to private Cambridge Associates data. While past performance doesn't guarantee future returns, it does suggest Glade Brook knows how to play late-stage cycles. In a market where many VCs are stuck in wait-and-see mode, Glade Brook appears to be playing offense betting that when the next wave breaks, it'll be the firms already in position that ride it the farthest. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Times
22-07-2025
- Business
- Business Times
Sanofi to buy Vicebio for up to US$1.6 billion in vaccine push
[PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology to streamline their development. The French drugmaker will pay US$1.15 billion upfront with a commitment for potential milestones worth as much as US$450 million, it said in a statement on Tuesday (Jul 22). Chief executive officer Paul Hudson is looking for innovation that fits with Sanofi's existing offerings, and Vicebio's experimental shots are intended to prevent several respiratory illnesses including RSV, the target of its new therapy Beyfortus. The deal is expected to close in the fourth quarter, and won't have a significant impact on Sanofi's financial guidance for the year, the company said. The transaction helps Sanofi get closer to making next-generation vaccines that offer protection against multiple respiratory viruses in a single shot that isn't mRNA – the technology behind the blockbuster Covid-19 immunisations. Vicebio's technology allows quicker development of liquid combination vaccines that can be stored at fridge temperatures, simplifying manufacturing and distribution by eliminating the need for freezing. The company is working on a single shot against RSV and human metapneumovirus, or hMPV, which is in an exploratory early-stage study. Like several rivals, Sanofi is focusing on cutting-edge therapies while divesting older medicines and its consumer-health division. BLOOMBERG
Yahoo
21-07-2025
- Business
- Yahoo
Sanofi (SNY) Expands Rare Disease Reach With $9.5B Blueprint Deal
We recently published Sanofi stands ninth on our list and is currently making waves for acquiring Blueprint for $9.5 billion. Sanofi (NASDAQ:SNY), a global biopharmaceutical leader headquartered in France with about 83,000 employees, is focused on immunology, oncology, rare diseases, and vaccines. The company continues to expand its innovative pipeline through internal research and strategic acquisitions. In June 2025, Sanofi (NASDAQ:SNY) announced its largest deal of the year, a $9.5 billion acquisition of U.S.-based Blueprint Medicines. This strategic move strengthens the company's position in rare immunological diseases. Blueprint adds to the business's portfolio Ayvakit/Ayvakyt (avapritinib), the only approved treatment for systemic mastocytosis (SM) in the U.S. and EU, along with promising pipeline assets like elenestinib and BLU-808, both targeting KIT-driven and other immune-related conditions. The acquisition also enhances the corporation's reach through Blueprint's existing relationships with allergists, dermatologists, and immunologists, aligning well with Sanofi (NASDAQ:SNY)'s goal to become a top player in immunology. CEO Paul Hudson called the deal a major step toward building a global immunology powerhouse. A closeup of pills in a pharmacy, representing the high quality medications of the company. This move complements the company's existing success with Dupixent (dupilumab), its flagship immunology drug, recently approved in the U.S. as the first targeted treatment for bullous pemphigoid. In addition, the business plans to invest at least $20 billion in the U.S. by 2030 to boost R&D, manufacturing, and new medicine launches, supporting growth and improving supply chain resilience. While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Daily Mail
17-07-2025
- Business
- Daily Mail
Car washes could be next after hosepipe ban if drought worsens: Water firms plan for worst-case scenario of switching off homes and erecting communal taps in the street
Parts of England currently under a hosepipe ban could face next steps of businesses being forced to stop washing cars and cleaning windows if the drought worsens. The latest ban begins tomorrow for South East Water customers in Kent and Sussex - joining the Yorkshire Water area which has had restrictions since last Friday. Southern Water will activate its own restrictions for Hampshire and the Isle of Wight from Monday; before Thames Water brings in its ban on Tuesday for customers in Oxfordshire, Gloucestershire, most of Wiltshire and some parts of Berkshire. Meteorologist Paul Hudson said a hosepipe ban normally results in a fall of 10 to 15 per cent in demand for water, according to figures from the water industry. The Look North presenter told BBC Radio Humberside: 'It is the first step and there are further steps that will be enacted if it doesn't rain over the coming weeks.' He added: 'The long-range forecast for July shows it's going to be yet another month of below-average rainfall. If we do not get decent rainfall in the coming weeks, then Yorkshire Water will have to move onto the next step in their drought plan.' Mr Hudson said the next step from Yorkshire Water would mean car washes and other businesses that use large amounts of water would have their licence removed. He explained that the aim of restrictions from the company was to 'try and slow the decline in reservoirs for a long enough period of time before, inevitably, the rains fall'. The Government makes all water companies produce a drought plan, which follows Environment Agency guidelines on what steps are taken if there is a lack of rain. Here are the five stages outlined in the Thames Water drought plan, to give an idea of what firms could be planning if the situation worsens over the coming months: 1) Impending drought Firms which believe restrictions could be required generally begin with an awareness campaign in the media to tell customers about an impending drought. People are encouraged to use water sparingly, and the message is put out through advertising on radio, newspapers, social media and other online channels. 2) Early drought The early stages of a drought will see this campaign stepped up as customers are urged to reduce water use through advice and installing water efficiency gadgets. The next step is a hosepipe ban – officially called a Temporary Use Ban (TUB) – which restricts the use of sprinklers and hosepipes in and around the home. This prohibits uses including watering gardens, topping up ponds, filling paddling pools and cleaning cars – although vulnerable customers are given exemptions. 3) Severe drought If the drought conditions worsen, then 'non-essential' water use for businesses would be restricted, meaning car washes may be forced to stop operating. This ban, called a Non-Essential Use Ban (NEUB), could also stop activities such as cleaning windows at industrial plants and suppressing dust on construction sites. The Government would have to grant a 'drought order' for these restrictions to be brought in, and customers would get at least ten weeks' notice. The water company would also apply to the Environment Agency for drought permits to allow it to take more water from certain sources. 4) Serious drought Additional measures could include stepping up actions to reduce demand and providing additional supplies to try to avoid reaching emergency restrictions. The company would bring in widespread communications asking customers to make significant reductions in their water use, cutting it by nearly half. There would be an aim for people to reduce usage by around 80 to 100 litres per person per day. On average, customers use around 140 litres per person per day. Bosses would also try to bring on additional supply, such as emergency raw water pipeline transfers, temporary desalination units and alternative sources. These would be for non-potable use such as toilet flushing or watering crops - in other words, water that is not appropriate for human consumption. 5) Extreme drought Thames Water said extreme measures would be the result of a drought worse than any on record going back to 1920, and the firm plans to 'never reach this level'. But they could reduce water use through 'rota cuts', when usage is restricted at certain periods of time, and standpipes in the street for customers to collect water. The drought plan notes that this would have a 'massive impact on society and the economy', and the government would need to grant an emergency drought order. The last time homes had had their water supply replaced by communal standpipes in the street was in Yorkshire, Devon and East Anglia during the heatwave of 1976. In addition, homes in Wales and western England had to make do without tap water for most of the day – and some firms were ordered to halve water consumption. Yesterday, Southern Water became the latest company to bring in a hosepipe ban, to protect rare chalk stream habitat. The company said restrictions on hosepipes for activities such as watering gardens, filling paddling pools or washing cars would come in for households in Hampshire and the Isle of Wight from Monday. It was the latest announcement by water companies bringing in hosepipe bans in response to the driest start to the year since 1976 for England. Rainfall across England was 20 per cent less than the long-term average for June, which was also the hottest on record for the country, with two heatwaves driving unusually high demand for water, the Environment Agency has said. Drought was declared in East and West Midlands on Tuesday, with the region joining swathes of northern England in drought status. Yorkshire Water became the first major water company to bring in a hosepipe ban which came into effect last Friday. South East Water has announced a hosepipe ban in Kent and Sussex from tomorrow. Thames Water is bringing in a ban from next Tuesday for customers in Oxfordshire, Gloucestershire, most of Wiltshire and some parts of Berkshire. Before this month, the last water company to have a hosepipe ban was South West Water, which lifted its ban in September 2023.
